Argenx Stock Falls After Phase 3 Sjögren’s Trial Stops
Argenx stops its Phase 3 UNITY trial of efgartigimod in Sjögren’s disease for futility; shares fell about 16%. What it means for the pipeline.
Argenx stops its Phase 3 UNITY trial of efgartigimod in Sjögren’s disease for futility; shares fell about 16%. What it means for the pipeline.